Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600dxk

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	Feb 24	PCTGEN now available on STN
NEWS 4	Feb 24	TEMA now available on STN
NEWS 5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 6	Feb 26	PCTFULL now contains images
NEWS 7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 8	Mar 24	PATDPAFULL now available on STN
NEWS 9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 10	Apr 11	Display formats in DGENE enhanced
NEWS 11	Apr 14	MEDLINE Reload
NEWS 12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 13	AUG 15	Indexing from 1937 to 1946 added to records in CA/CAPLUS
NEWS 14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 15	Apr 28	RDISCLOSURE now available on STN
NEWS 16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 19	May 19	Simultaneous left and right truncation added to WSCA
NEWS 20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS 21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS 22	Jun 06	PASCAL enhanced with additional data
NEWS 23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS 24	Jun 25	HSDB has been reloaded
NEWS 25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS 26	Jul 21	Identification of STN records implemented
NEWS 27	Jul 21	Polymer class term count added to REGISTRY
NEWS 28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS 29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS 30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS 31	AUG 15	PATDPAFULL: one FREE connect hour, per account, in September 2003
NEWS 32	AUG 15	PCTGEN: one FREE connect hour, per account, in September 2003
NEWS 33	AUG 15	RDISCLOSURE: one FREE connect hour, per account, in September 2003
NEWS 34	AUG 15	TEMA: one FREE connect hour, per account, in September 2003
NEWS 35	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS 36	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS 37	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS 38	AUG 18	Simultaneous left and right truncation added to ANABSTR

```
 NEWS EXPRESS  April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
               MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:55:20 ON 20 AUG 2003

=> fil .carb
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'MEDLINE' ENTERED AT 14:55:30 ON 20 AUG 2003

FILE 'BIOSIS' ENTERED AT 14:55:30 ON 20 AUG 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHDS' ENTERED AT 14:55:30 ON 20 AUG 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'CAPLUS' ENTERED AT 14:55:30 ON 20 AUG 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s imatinib(w)mesylate?
L1          810 IMATINIB(W) MESYLATE?

=> s l1 and leukemia?
L2          655 L1 AND LEUKEMIA?

=> s decitabine?
L3          208 DECITABINE?

=> s l2 and l3
L4            7 L2 AND L3

=> d l4 abs ibib 1-7

L4   ANSWER 1 OF 7     MEDLINE on STN
AB   Chronic myeloid leukemia (CML) typically runs a biphasic or
     triphasic course, with diagnoses usually made in the chronic phase (CP).
     Without effective treatment, patients eventually progress to a blastic
     phase (BP), frequently through an intermediate or accelerated phase (AP).
     Because the definition of AP varies among studies, comparisons of outcome
     and prognosis are difficult.  The management of patients in these advanced
     phases of the disease has been much less satisfactory than that of
     patients in CP.  Treatment with interferon-alfa (IFNalpha)-based therapy
     is ineffective for most patients in AP and for all of those in BP.
```

Imatinib mesylate has demonstrated significant activity AP and BP disease, although the results are inferior compared to treatment in CP. In AP, 82% of patients achieve a hematologic response, with 24% achieving a major cytogenetic remission (MCR). Early MCR (within 3 months of diagnosis) provides a survival advantage over patients who do not achieve this response or achieve it later. In BP, 21% of previously treated patients and 36% of previously untreated patients have responded to imatinib, and up to 17% of patients may achieve a major cytogenetic response. However, responses are frequently short-lived. Several agents are being investigated for treatment of advanced-phase CML, including **decitabine** (DAC), homoharringtonine (HHT), troxacitabine, clofarabine, farnesyl transferase (FTase) inhibitors (FTI), and others. Many have also proven to be synergistic with imatinib in vitro and combination studies are ongoing. Continued investigation of these approaches is needed to improve the long-term prognosis of advanced-phase CML. Semin Hematol 40:79-86.

ACCESSION NUMBER: 2003053879 IN-PROCESS
DOCUMENT NUMBER: 22451283 PubMed ID: 12563614
TITLE: Advanced-phase chronic myeloid **leukemia**.
AUTHOR: Cortes Jorge; Kantarjian Hagop
CORPORATE SOURCE: Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX.
SOURCE: SEMINARS IN HEMATOLOGY, (2003 Jan) 40 (1) 79-86. Journal code: 0404514. ISSN: 0037-1963.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20030204
Last Updated on STN: 20030204

L4 ANSWER 2 OF 7 MEDLINE on STN

AB The treatment options for chronic myelogenous **leukemia** (CML) continue to evolve rapidly. **Imatinib mesylate** (Gleevec, Glivec, formerly STI571) has continued to show remarkable clinical benefits and the updated results with this agent are reviewed. As relapses using single agent imatinib have occurred, particularly in advanced phase patients, the issue of whether combinations of other antileukemic agents with imatinib may yield improved results is addressed. In addition, data on new agents that have potential in the treatment of CML are reviewed. These agents are presented in the context of their molecular mechanism of action. The most recent data for stem cell transplantation, along with advances in nonmyeloablative transplants, are also reviewed. In Section I, Drs. Stephen O'Brien and Brian Druker update the current status of clinical trials with imatinib and review ongoing investigations into mechanisms of resistance and combinations of imatinib with other agents. They also present their views on integration of imatinib with other therapies. In Section II, Dr. Jorge Cortes describes the most recent data on novel therapies for CML, including farnesyl transferase inhibitors, arsenic trioxide, **decitabine**, and troxatyl, among others. These agents are discussed in the context of their molecular mechanism of action and rationale for use. In Section III, Dr. Jerald Radich updates the results of stem cell transplants for CML, including emerging data on nonmyeloablative transplants. He also presents data on using microarrays to stratify patients into molecularly defined risk groups.

ACCESSION NUMBER: 2002687859 IN-PROCESS
DOCUMENT NUMBER: 22335953 PubMed ID: 12446421
TITLE: Chronic myelogenous **leukemia**.
AUTHOR: Druker Brian J; O'Brien Stephen G; Cortes Jorge; Radich Jerald
CORPORATE SOURCE: University of Newcastle, Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom.
SOURCE: Hematology (Am Soc Hematol Educ Program), (2002) 111-35.

Journal code: 100890099. ISSN: 1520-4391.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: IN-PROCESS; NONINDEXED; Priority Journals
ENTRY DATE: Entered STN: 20021214
Last Updated on STN: 20030713

L4 ANSWER 3 OF 7 MEDLINE on STN
AB Chronic myelogenous **leukemia** (CML) is a clonal myeloproliferative disorder molecularly defined by the BCR-ABL gene and its products. The protein encoded by this chimeric gene is a constitutively activated tyrosine kinase that alters multiple signal transduction pathways inducing malignant transformation. Until recently, treatment options for patients with CML consisted of hydroxyurea, interferon-based therapies or allogeneic stem cell transplantation (alloSCT). Treatment decisions were generally based on the age of the patient and the phase of the disease. Recently, several new therapies have been developed that may change the natural history of CML and patient prognosis. In particular **imatinib mesylate** (ST1571, Gleevec) an oral Bcr-Abl kinase inhibitor, has demonstrated activity in all phases of CML, and may replace interferon and alloSCT as the initial therapy for this disease. Other agents and therapies with potential value, either alone or in combination, include polyethyleneglycol (PEG) interferon, homoharringtonine, **decitabine**, oral cytarabine, and growth factor modulation. In this article, we discuss the biological and clinical characteristics of CML, as well as the different therapeutic alternatives for patients with this disorder.
ACCESSION NUMBER: 2002254399 MEDLINE
DOCUMENT NUMBER: 21989084 PubMed ID: 11993784
TITLE: Current therapy of chronic myelogenous **leukemia**.
AUTHOR: Garcia-Manero Guillermo; Talpaz Moshe; Kantarjian Hagop M
CORPORATE SOURCE: Department of Leukemia and Bioimmunotherapy, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
SOURCE: INTERNAL MEDICINE, (2002 Apr) 41 (4) 254-64. Ref: 81
Journal code: 9204241. ISSN: 0918-2918.
PUB. COUNTRY: Japan
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200211
ENTRY DATE: Entered STN: 20020508
Last Updated on STN: 20021211
Entered Medline: 20021104

L4 ANSWER 4 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AB Clinical phase I/II studies with the Abl kinase inhibitor **imatinib mesylate** (Gleevec/Glivec, formerly ST1571) for the treatment for chronic myelogenous **leukemia** (CML) demonstrated the safety and the remarkable efficacy of this molecularly targeted agent. However, a significant proportion of patients treated in the chronic phase of the disease after having failed interferon alpha (IFN) remain predominantly Philadelphia chromosome positive (Ph+), suggesting a risk of later relapses. Furthermore, results in blast crisis patients revealed a high frequency of relapses or resistance to imatinib. To circumvent resistance, improve response rates, or prolong survival, pre-clinical evaluations of combinations of imatinib with other agents have been pursued. Some of these have already been translated into clinical studies. Here, we first summarize evidence from pre-clinical studies on new combination regimens with imatinib in the treatment of CML. Second, we analyze preliminary clinical data of ongoing combination studies. Finally, we provide a summary of approaches that use novel antileukemic agents with molecularly characterized modes of action.

ACCESSION NUMBER: 2002:478536 BIOSIS
DOCUMENT NUMBER: PREV200200478536
TITLE: Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor **imatinib mesylate** (Gleevec/Glivec) in chronic myelogenous **leukemia**: A translational perspective.
AUTHOR(S): La Rosee, P.; O'Dwyer, M. E.; Druker, B. J. (1)
CORPORATE SOURCE: (1) Division of Hematology and Medical Oncology, Orgeon Health and Science University, 3181 Sam Jackson Park Rd, Mail Code L592, Portland, OR, 97201 USA
SOURCE: Leukemia (Basingstoke), (July, 2002) Vol. 16, No. 7, pp. 1213-1219. http://www.naturesj.com/leu/index.html. print. ISSN: 0887-6924.
DOCUMENT TYPE: General Review
LANGUAGE: English

L4 ANSWER 5 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AB Chronic myelogenous **leukemia** (CML) is a clonal myeloproliferative disorder molecularly defined by the BCR-ABL gene and its products. The protein encoded by this chimeric gene is a constitutively activated tyrosine kinase that alters multiple signal transduction pathways inducing malignant transformation. Until recently, treatment options for patients with CML consisted of hydroxyurea, interferon-based therapies or allogeneic stem cell transplantation (alloSCT). Treatment decisions were generally based on the age of the patient and the phase of the disease. Recently, several new therapies have been developed that may change the natural history of CML and patient prognosis. In particular **imatinib mesylate** (STI571, Gleevec) an oral Bcr-Abl kinase inhibitor, has demonstrated activity in all phases of CML, and may replace interferon and alloSCT as the initial therapy for this disease. Other agents and therapies with potential value, either alone or in combination, include polyethyleneglycol (PEG) interferon, homoharringtonine, **decitabine**, oral cytarabine, and growth factor modulation. In this article, we discuss the biological and clinical characteristics of CML, as well as the different therapeutic alternatives for patients with this disorder.
ACCESSION NUMBER: 2002:376988 BIOSIS
DOCUMENT NUMBER: PREV200200376988
TITLE: Current therapy of chronic myelogenous **leukemia**.
AUTHOR(S): Garcia-Manero, Guillermo; Talpaz, Moshe; Kantarjian, Hagop M. (1)
CORPORATE SOURCE: (1) Department of Leukemia, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX, 77030 USA
SOURCE: Internal Medicine (Tokyo), (April, 2002) Vol. 41, No. 4, pp. 254-264. print. ISSN: 0918-2918.
DOCUMENT TYPE: General Review
LANGUAGE: English

L4 ANSWER 6 OF 7 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AB 237 adult patients (pts) with Ph+ CML AP were treated with **imatinib mesylate** 400-600 mg P.O. daily at our institution as part of 2 Novartis sponsored multi-institutional multinational studies: Novartis 109 the pivotal study (N=58) and Novartis 114 the expanded access study (N=179). 193 pts are evaluable with more than 3 months of follow-up. 156 pts had the classical CML AP criteria (Cancer 61:1441, 1988); 33 pts were treated for blasts 10-14%, blasts+pros 20-29%, or spleen gtoreq10 cm bcm or 50% increase over 4 weeks (modified CML-AP criteria); 4 pts had second chronic phase. 26 received **imatinib mesylate** 400 mg/D, and 167 pts had **imatinib mesylate** 600 mg/D. Their median age was 50 years. Overall, 162 pts (84%) achieved CHR, 107 (55%) had a cytogenetic response (Ph<90%): major (Ph<35%) in 79 (41%); complete (Ph 0%) in 57

(30%). With a median follow up of 8.4 months, 167 patients (87%) are alive. The estimated 1.5-year survival rate was 75%, and remission duration rate 61%. Prognostic factors associated with lower major CG response rates (pgtoreq0.02) were: age gtoreq60 yrs, splenomegaly gtoreq10 cm bcm, longer duration of chronic phase >3 yrs, WBC >10X109/L, marrow blasts gtoreq15%, and STI dose 400 mg daily. Prognostic factors associated with worse survival (p<0.02) were: age gtoreq60 yrs, hemoglobin <10 g/dl marrow blasts gtoreq15%, cytogenetic clonal evolution and STI dose 400 mg daily and failure to achieve major CG response. Patients treated with 600 vs 400 mg had significantly better major (44% vs 19%, p=0.02) and complete (32% vs 15%, p=0.11) CG response rates, and 1.5 yr survival rates (78% vs 67%, p<0.01). Patients with "modified" CML AP criteria had similar major CG response and survival rates. By multivariate analysis, factors independently predictive negatively for major CG response were (p<0.05): diagnosis to therapy >3 years, and spleen size >10 cm bcm. Those associated with worse survival were (p<0.05): older age, failure to achieve major cytogenetic response, and cytogenetic clonal evolution. In summary **imatinib mesylate** is the most active single agent therapy in accelerated phase. **Imatinib mesylate** combinations with interferon alpha, cytarabine, homoharringtonine, **decitabine** or others are warranted in CML AP.

ACCESSION NUMBER: 2002:153049 BIOSIS
DOCUMENT NUMBER: PREV200200153049
TITLE: Treatment of accelerated phase of Philadelphia chromosome positive chronic myeloid **leukemia** (Ph+ CML AP) with **imatinib mesylate** (STI571.
AUTHOR(S): Kantarjian, Hagop M. (1); O'Brien, Susan (1); Cortes, Jorge (1); Faderl, Stefan (1); Giles, Francis (1); Thomas, Deborah (1); Garcia-Manero, Guillermo (1); Albitar, Maher; Rios, Mary Beth (1); Shan, Jenny (1); Issa, Jean-Pierre (1); Resta, Debra; Capdeville, Renaud; Keating, Michael J. (1); Freireich, Emil J. (1); Talpaz, Moshe
CORPORATE SOURCE: (1) Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX USA
SOURCE: Blood, (November 16, 2001) Vol. 98, No. 11 Part 1, pp. 141a. http://www.bloodjournal.org/. print.
Meeting Info.: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001
ISSN: 0006-4971.
DOCUMENT TYPE: Conference
LANGUAGE: English

L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AB Methods, compns. and kits are provided for treating cancer assocd. with protein tyrosine kinase activity such as chronic myelogenous **leukemia**. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous **leukemia** and a degree of resistance to **imatinib mesylate**, a therapeutically effective amt. of a DNA methylation inhibitor which mitigates the **imatinib mesylate** resistance.

ACCESSION NUMBER: 2003:609844 CAPLUS
TITLE: Method for treating chronic myelogenous **leukemia** combined with some resistance to **imatinib mesylate** using DNA methylation inhibitor to mitigate **imatinib mesylate** resistance
INVENTOR(S): Lyons, John
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003147813	A1	20030807	US 2002-71849	20020207
WO 2003065995	A2	20030814	WO 2003-US3537	20030206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-71849 A1 20020207
US 2002-206854 A1 20020726

=> s l2 and treatment?
L5 436 L2 AND TREATMENT?

=> s l2 and dna(w)methylation?
L6 3 L2 AND DNA(W) METHYLATION?

=> d l6 abs ibib 1-3

L6 ANSWER 1 OF 3 MEDLINE on STN

AB Very promising results have been obtained in clinical trials on chronic-phase chronic myeloid **leukemia** (CP-CML) patients treated with **imatinib mesylate** (IM; Gleevecr, STI571), a BCR-ABL tyrosine kinase inhibitor. However, we found that IM caused considerable inhibition of normal hematopoietic progenitor cells upon treating control bone marrow (BM) cultures. In vitro IM treatment gave a decrease in the yield and size of colonies from BM of untreated CP-CML patients that was only two to three times that from the normal samples. Moreover, about 30% of myeloid progenitors (CFU-GM) from CML BM still formed colonies in the presence of IM, most of which had BCR-ABL RNA. About half of these treated colonies also displayed methylation of the internal ABL Pa promoter, a CML-specific epigenetic alteration, which was used in this study as a marker for BCR-ABL translocation-containing cells. However, 5-8% of the treated or the untreated CML BM-derived colonies had no detectable BCR-ABL RNA by two or three rounds of RT-PCR despite being positive for the internal standard RNA and displaying hallmarks of CML, either t(9;22)(q34;ql 1) or ABL Pa methylation. Our results indicate that IM is only partially specific for CML progenitor cells compared to normal hematopoietic progenitor cells and suggest that some CML cells may have a silent BCR-ABL oncogene that could interfere with therapy.

ACCESSION NUMBER: 2003156874 MEDLINE
DOCUMENT NUMBER: 22560189 PubMed ID: 12673129
TITLE: Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
COMMENT: Comment in: Cancer Biol Ther. 2003 Jan-Feb;2(1):109-10
AUTHOR: Jiang Guanchao; Yang Fan; Li Marilyn; Weissbecker Karen; Price Sherrie; Kim K C; La Russa Vincent F; Safah Hana; Ehrlich Melanie
CORPORATE SOURCE: Tulane Cancer Center and Humon Genetics Program, Tulane Medical School, New Orleans, Lousiana 70112, USA.
CONTRACT NUMBER: CA78639 (NCI)
CA81506 (NCI)
SOURCE: Cancer Biol Ther, (2003 Jan-Feb) 2 (1) 103-8.
Journal code: 101137842. ISSN: 1538-4047.

PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200307
ENTRY DATE: Entered STN: 20030404
Last Updated on STN: 20030724
Entered Medline: 20030723

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AB Methods are provided for treating diseases associated with abnormal activity of kinases such as chronic myelogenous **leukemia**. The method comprises: administering a **DNA methylation** inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor such as **imatinib mesylate** to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3'-kinase (P13K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.
ACCESSION NUMBER: 2003:633416 CAPLUS
TITLE: Method for treating diseases associated with abnormal kinase activity
INVENTOR(S): Lyons, John; Rubinfeld, Joseph
PATENT ASSIGNEE(S): Supergen, Inc., USA
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003065995	A2	20030814	WO 2003-US3537	20030206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003147813	A1	20030807	US 2002-71849	20020207

PRIORITY APPLN. INFO.: US 2002-71849 A1 20020207
US 2002-206854 A1 20020726

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AB Methods, compns. and kits are provided for treating cancer assocd. with protein tyrosine kinase activity such as chronic myelogenous **leukemia**. In particular, a treatment method is provided comprising: administering to a patient having chronic myelogenous **leukemia** and a degree of resistance to **imatinib mesylate**, a therapeutically effective amt. of a **DNA**

methylation inhibitor which mitigates the **imatinib mesylate** resistance.

ACCESSION NUMBER: 2003:609844 CAPLUS
TITLE: Method for treating chronic myelogenous **leukemia** combined with some resistance to **imatinib mesylate** using **DNA methylation** inhibitor to mitigate **imatinib mesylate** resistance
INVENTOR(S): Lyons, John
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003147813	A1	20030807	US 2002-71849	20020207
WO 2003065995	A2	20030814	WO 2003-US3537	20030206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-71849 A1 20020207
US 2002-206854 A1 20020726

=> s dna(w)methylation and l1
L7 3 DNA(W) METHYLATION AND L1

=> d l7 1-3

L7 ANSWER 1 OF 3 MEDLINE on STN
AN 2003156874 MEDLINE
DN 22560189 PubMed ID: 12673129
TI Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
CM Comment in: Cancer Biol Ther. 2003 Jan-Feb;2(1):109-10
AU Jiang Guanchao; Yang Fan; Li Marilyn; Weissbecker Karen; Price Sherrie; Kim K C; La Russa Vincent F; Safah Hana; Ehrlich Melanie
CS Tulane Cancer Center and Humon Genetics Program, Tulane Medical School, New Orleans, Lousiana 70112, USA.
NC CA78639 (NCI)
CA81506 (NCI)
SO Cancer Biol Ther, (2003 Jan-Feb) 2 (1) 103-8.
Journal code: 101137842. ISSN: 1538-4047.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200307
ED Entered STN: 20030404
Last Updated on STN: 20030724
Entered Medline: 20030723

L7 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

AN 2003:633416 CAPLUS
TI Method for treating diseases associated with abnormal kinase activity
IN Lyons, John; Rubinfeld, Joseph
PA Supergen, Inc., USA
SO PCT Int. Appl., 64 pp.
    CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003065995	A2	20030814	WO 2003-US3537	20030206
	US 2003147813	A1	20030807	US 2002-71849	20020207
PRAI	US 2002-71849	A1	20020207		
	US 2002-206854	A1	20020726		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

L7 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:609844 CAPLUS
TI Method for treating chronic myelogenous leukemia combined with some resistance to **imatinib mesylate** using **DNA methylation** inhibitor to mitigate **imatinib mesylate** resistance
IN Lyons, John
PA USA
SO U.S. Pat. Appl. Publ., 10 pp.
    CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003147813	A1	20030807	US 2002-71849	20020207
	WO 2003065995	A2	20030814	WO 2003-US3537	20030206
PRAI	US 2002-71849	A1	20020207		
	US 2002-206854	A1	20020726		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

=> s dna(w)methylation and inhibitor?
L8 2446 DNA(W) METHYLATION AND INHIBITOR?

=> s l8 and l1
L9 3 L8 AND L1

```
=> s l9 1-3
MISSING OPERATOR L9 1-3
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l9 1-3

L9   ANSWER 1 OF 3     MEDLINE on STN
AN   2003156874     MEDLINE
DN   22560189   PubMed ID: 12673129
TI   Imatinib (ST1571) provides only limited selectivity for CML cells and
     treatment might be complicated by silent BCR-ABL genes.
CM   Comment in: Cancer Biol Ther. 2003 Jan-Feb;2(1):109-10
AU   Jiang Guanchao; Yang Fan; Li Marilyn; Weissbecker Karen; Price Sherrie;
     Kim K C; La Russa Vincent F; Safah Hana; Ehrlich Melanie
CS   Tulane Cancer Center and Humon Genetics Program, Tulane Medical School,
     New Orleans, Lousiana 70112, USA.
NC   CA78639 (NCI)
     CA81506 (NCI)
SO   Cancer Biol Ther, (2003 Jan-Feb) 2 (1) 103-8.
     Journal code: 101137842. ISSN: 1538-4047.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
LA   English
FS   Priority Journals
EM   200307
ED   Entered STN: 20030404
     Last Updated on STN: 20030724
     Entered Medline: 20030723

L9   ANSWER 2 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:633416  CAPLUS
TI   Method for treating diseases associated with abnormal kinase activity
IN   Lyons, John; Rubinfeld, Joseph
PA   Supergen, Inc., USA
SO   PCT Int. Appl., 64 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 2
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2003065995     A2    20030814       WO 2003-US3537   20030206
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD,
             RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
             CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
             NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
             ML, MR, NE, SN, TD, TG
     US 2003147813     A1    20030807       US 2002-71849    20020207
PRAI US 2002-71849     A1    20020207
     US 2002-206854    A1    20020726

L9   ANSWER 3 OF 3  CAPLUS  COPYRIGHT 2003 ACS on STN
AN   2003:609844  CAPLUS
TI   Method for treating chronic myelogenous leukemia combined with some
     resistance to imatinib mesylate using DNA
     methylation inhibitor to mitigate imatinib
     mesylate resistance
IN   Lyons, John
```

PA USA
SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003147813	A1	20030807	US 2002-71849	20020207
WO 2003065995	A2	20030814	WO 2003-US3537	20030206

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-71849 A1 20020207
US 2002-206854 A1 20020726

=> s myelogenous(w)leukemia and staged?
L10 3 MYELOGENOUS(W) LEUKEMIA AND STAGED?

=> s myelogenous(w)leukemia?
L11 24614 MYELOGENOUS(W) LEUKEMIA?

=> s l11 and cytidine?
L12 70 L11 AND CYTIDINE?

=> d l12 1-70

L12 ANSWER 1 OF 70 MEDLINE on STN
AN 2002222196 MEDLINE
DN 21956901 PubMed ID: 11960335
TI Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic **myelogenous leukemia** patients in chronic phase.
AU Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Briere J; Abgrall J F; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque J P; Delain M; Harousseau J L; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F
CS Division of Hematology, University Hospital of Strasbourg, France. (France Intergroupe des Leucemies Myeloides Chroniques).
SO LEUKEMIA, (2002 Apr) 16 (4) 573-80.
Journal code: 8704895. ISSN: 0887-6924.
CY England: United Kingdom
DT (CLINICAL TRIAL)
(CLINICAL TRIAL, PHASE II)
Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200205
ED Entered STN: 20020418
Last Updated on STN: 20020508
Entered Medline: 20020507

L12 ANSWER 2 OF 70 MEDLINE on STN
AN 2002206547 MEDLINE
DN 21936329 PubMed ID: 11939268
TI Bone marrow cytogenetic complete remission achieved by interferon-alpha

plus cytarabine ocfosfate therapy in a patient with chronic **myelogenous leukemia** during extramedullary blast crisis.
AU Gotoh Akihiko; Miyazawa Keisuke; Uchida Yoshiko; Sashida Goro; Kawakubo Ken; Kuriyama Yuzuru; Ohyashiki Kazuma
CS First Department of Internal Medicine, Tokyo Medical University, Japan.
SO INTERNATIONAL JOURNAL OF HEMATOLOGY, (2002 Feb) 75 (2) 191-4.
Journal code: 9111627. ISSN: 0925-5710.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200301
ED Entered STN: 20020410
Last Updated on STN: 20030125
Entered Medline: 20030124

L12 ANSWER 3 OF 70 MEDLINE on STN
AN 2001238195 MEDLINE
DN 21218123 PubMed ID: 11320667
TI Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low **cytidine** deaminase activity.
AU Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
CS BioChem Pharma Inc., 275 Armand-Frappier Blvd, Laval, Quebec H7V 4A7, Canada.. gourdeah@biochempharma.com
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY, (2001 Mar) 47 (3) 236-40.
Journal code: 7806519. ISSN: 0344-5704.
CY Germany: Germany, Federal Republic of
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200105
ED Entered STN: 20010517
Last Updated on STN: 20020420
Entered Medline: 20010503

L12 ANSWER 4 OF 70 MEDLINE on STN
AN 2001100720 MEDLINE
DN 21036706 PubMed ID: 11196156
TI Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
AU Takemura H; Urasaki Y; Yoshida A; Fukushima T; Ueda T
CS First Department of Internal Medicine, Fukui Medical University, Matsuoka, Japan.
SO CANCER RESEARCH, (2001 Jan 1) 61 (1) 172-7.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200102
ED Entered STN: 20010322
Last Updated on STN: 20010322
Entered Medline: 20010201

L12 ANSWER 5 OF 70 MEDLINE on STN
AN 2000421721 MEDLINE
DN 20327793 PubMed ID: 10867132
TI Treatment of patients with advanced chronic **myelogenous leukemia** with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study.
AU Kuhr T; Eisterer W; Apfelbeck U; Linkesch W; Bechter O; Zabernigg A; Geissler K; Barbieri G; Duba C; Gastl G; Thaler J
CS Department of Internal Medicine, University Hospital, Anichstrasse 35,

6020, Innsbruck, Austria.. thomas.kuehr@uibk.ac.at
SO LEUKEMIA RESEARCH, (2000 Jul) 24 (7) 583-7.
Journal code: 7706787. ISSN: 0145-2126.
CY ENGLAND: United Kingdom
DT (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(MULTICENTER STUDY)
LA English
FS Priority Journals
EM 200009
ED Entered STN: 20000915
Last Updated on STN: 20000915
Entered Medline: 20000907

L12 ANSWER 6 OF 70 MEDLINE on STN
AN 2000084096 MEDLINE
DN 20084096 PubMed ID: 10616723
TI Isolation and characterization of 5-carbamoylmethyluridine and 5-carbamoylmethyl-2-thiouridine from human urine.
AU Chheda G B; Patrzyc H B; Tworek H A; Dutta S P
CS Department of Biophysics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
SO NUCLEOSIDES AND NUCLEOTIDES, (1999 Oct) 18 (10) 2155-73.
Journal code: 8215930. ISSN: 0732-8311.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200002
ED Entered STN: 20000229
Last Updated on STN: 20000229
Entered Medline: 20000214

L12 ANSWER 7 OF 70 MEDLINE on STN
AN 1998339469 MEDLINE
DN 98339469 PubMed ID: 9676847
TI Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute **myelogenous leukemia**.
AU Gandhi V; Xu Y Z; Estey E
CS Department of Clinical Investigation, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
NC CA32839 (NCI)
CA55164 (NCI)
CA57629 (NCI)
SO CLINICAL CANCER RESEARCH, (1998 Jul) 4 (7) 1719-26.
Journal code: 9502500. ISSN: 1078-0432.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199809
ED Entered STN: 19980925
Last Updated on STN: 19980925
Entered Medline: 19980916

L12 ANSWER 8 OF 70 MEDLINE on STN
AN 1998240988 MEDLINE
DN 98240988 PubMed ID: 9581832
TI Telomerase from human leukemia cells: properties and its interaction with deoxynucleoside analogues.
AU Pai R B; Pai S B; Kukhanova M; Dutschman G E; Guo X; Cheng Y C
CS Department of Pharmacology, Yale School of Medicine, Yale University, New Haven, Connecticut 06510, USA.
NC AI-38204 (NIAID)

SO CANCER RESEARCH, (1998 May 1) 58 (9) 1909-13.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199806
ED Entered STN: 19980611
Last Updated on STN: 19980611
Entered Medline: 19980602

L12 ANSWER 9 OF 70 MEDLINE on STN
AN 97083073 MEDLINE
DN 97083073 PubMed ID: 8929647
TI Combination therapy with granulocyte colony-stimulating factor, all-trans retinoic acid, and low-dose cytotoxic drugs for acute **myelogenous leukemia**.
AU Usuki K; Kitazume K; Endo M; Ito K; Iki S; Urabe A
CS Division of Hematology, Kanto Teishin Hospital, Tokyo.
SO INTERNAL MEDICINE, (1995 Dec) 34 (12) 1186-9.
Journal code: 9204241. ISSN: 0918-2918.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199703
ED Entered STN: 19970407
Last Updated on STN: 19970407
Entered Medline: 19970324

L12 ANSWER 10 OF 70 MEDLINE on STN
AN 95275050 MEDLINE
DN 95275050 PubMed ID: 7755392
TI Low-dose cytarabine ocfosfate therapy in an elderly acute **myelogenous leukemia**.
AU Hamaoka R; Jozaki K; Amano T; Itoh H; Imai Y; Nishikawa M; Kurokawa M; Yonezawa T; Chinen Y
CS Dept. of Internal Medicine, Ikeda Municipal Hospital.
SO GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], (1995 May) 22 (6) 819-22.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals
EM 199506
ED Entered STN: 19950629
Last Updated on STN: 19950629
Entered Medline: 19950616

L12 ANSWER 11 OF 70 MEDLINE on STN
AN 94175542 MEDLINE
DN 94175542 PubMed ID: 8129396
TI Successful treatment of acute **myelogenous leukemia** in an elderly patient with cytarabine ocfosfate.
AU Inaba T; Shimazaki C; Tatsumi T; Yamagata N; Hirata T; Goto H; Fujita N; Nakagawa M; Fujita N; Miyazaki S; +
CS Second Dept. of Medicine, Kyoto Prefectural University of Medicine.
SO GAN TO KAGAKU RYOHO [JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY], (1994 Mar) 21 (4) 535-8.
Journal code: 7810034. ISSN: 0385-0684.
CY Japan
DT Journal; Article; (JOURNAL ARTICLE)
LA Japanese
FS Priority Journals

EM 199404
ED Entered STN: 19940420
Last Updated on STN: 19940420
Entered Medline: 19940412

L12 ANSWER 12 OF 70 MEDLINE on STN
AN 94034807 MEDLINE
DN 94034807 PubMed ID: 8220157
TI Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors.
AU Cyopick P; Culliton R; Brockhausen I; Sutherland D R; Mills G B; Baker M
CS Toronto Hospital, Ontario, Canada.
SO LEUKEMIA AND LYMPHOMA, (1993 Sep) 11 (1-2) 79-90.
Journal code: 9007422. ISSN: 1042-8194.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199312
ED Entered STN: 19940117
Last Updated on STN: 19970203
Entered Medline: 19931207

L12 ANSWER 13 OF 70 MEDLINE on STN
AN 91339133 MEDLINE
DN 91339133 PubMed ID: 1873797
TI Hemin enhances the sensitivity of erythroleukemia cells to 1-beta-D-arabinofuranosylcytosine by both activation of deoxycytidine kinase and reduction of **cytidine** deaminase activity.
AU Honma Y; Onozuka Y; Okabe-Kado J; Kasukabe T; Hozumi M
CS Department of Chemotherapy, Saitama Cancer Center Research Institute, Japan.
SO CANCER RESEARCH, (1991 Sep 1) 51 (17) 4535-8.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199109
ED Entered STN: 19911013
Last Updated on STN: 19980206
Entered Medline: 19910923

L12 ANSWER 14 OF 70 MEDLINE on STN
AN 91199087 MEDLINE
DN 91199087 PubMed ID: 1707752
TI Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
AU Parker W B; Shaddix S C; Chang C H; White E L; Rose L M; Brockman R W; Shortnacy A T; Montgomery J A; Secrist J A 3rd; Bennett L L Jr
CS Kettering-Meyer Laboratory, Southern Research Institute, Birmingham, Alabama 35205.
NC CA34200 (NCI)
SO CANCER RESEARCH, (1991 May 1) 51 (9) 2386-94.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199105
ED Entered STN: 19910607
Last Updated on STN: 19980206
Entered Medline: 19910517

L12 ANSWER 15 OF 70 MEDLINE on STN
AN 91004045 MEDLINE
DN 91004045 PubMed ID: 2208147
TI Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
AU Grunewald R; Kantarjian H; Keating M J; Abbruzzese J; Tarassoff P; Plunkett W
CS Department of Medical Oncology, University of Texas, M.D. Anderson Cancer Center, Houston 77030.
NC CA32839 (NCI)
SO CANCER RESEARCH, (1990 Nov 1) 50 (21) 6823-6.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199011
ED Entered STN: 19910117
Last Updated on STN: 19910117
Entered Medline: 19901121

L12 ANSWER 16 OF 70 MEDLINE on STN
AN 90335802 MEDLINE
DN 90335802 PubMed ID: 2379165
TI Human leukemic myeloblasts and myeloblastoid cells contain the enzyme **cytidine** 5'-monophosphate-N-acetylneuraminic acid:Gal beta 1-3GalNAc alpha (2-3)-sialyltransferase.
AU Kanani A; Sutherland D R; Fibach E; Matta K L; Hindenburg A; Brockhausen I; Kuhns W; Taub R N; van den Eijnden D H; Baker M A
CS Department of Medicine, Toronto General Hospital, Ontario, Canada.
NC CA31762 (NCI)
CA35329 (NCI)
SO CANCER RESEARCH, (1990 Aug 15) 50 (16) 5003-7.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199009
ED Entered STN: 19901012
Last Updated on STN: 19980206
Entered Medline: 19900912

L12 ANSWER 17 OF 70 MEDLINE on STN
AN 88310800 MEDLINE
DN 88310800 PubMed ID: 2457428
TI Effect of HpaII and MspI restriction endonucleases on chronic **myelogenous leukemia** chromosomes. Detection of CpG dinucleotide demethylation in situ.
AU Ferrucci L; Mezzanotte R; Vanni R; Stuppia R; Guanciali-Franchi P; Calabrese G; Palka G; Bianchi U; Sumner A T
CS Dipartimento di Biologia, Facolta di Science M.F.N., II Universita di Roma, Italy.
SO CANCER GENETICS AND CYTOGENETICS, (1988 Sep) 34 (2) 251-6.
Journal code: 7909240. ISSN: 0165-4608.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198810
ED Entered STN: 19900308
Last Updated on STN: 19960129
Entered Medline: 19881007

L12 ANSWER 18 OF 70 MEDLINE on STN
AN 87187152 MEDLINE
DN 87187152 PubMed ID: 3471317
TI Presence of **cytidine** 5'-monophospho-N-acetylneuraminic acid:Gal beta 1-3GalNAc-R alpha(2-3)-sialyltransferase in normal human leukocytes and increased activity of this enzyme in granulocytes from chronic **myelogenous leukemia** patients.
AU Baker M A; Kanani A; Brockhausen I; Schachter H; Hindenburg A; Taub R N
NC CA 31761 (NCI)
CA 37162 (NCI)
SO CANCER RESEARCH, (1987 Jun 1) 47 (11) 2763-6.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198706
ED Entered STN: 19900303
Last Updated on STN: 19980206
Entered Medline: 19870625

L12 ANSWER 19 OF 70 MEDLINE on STN
AN 82048392 MEDLINE
DN 82048392 PubMed ID: 6945901
TI An in vitro model for acute **myelogenous leukemia** chemotherapy.
AU Koeffler H P; Yen J; Lowe L
NC CA-15619 (NCI)
CA-15688 (NCI)
CA-16043 (NCI)
+
SO CANCER, (1981 Nov 1) 48 (9) 1958-63.
Journal code: 0374236. ISSN: 0008-543X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 198201
ED Entered STN: 19900316
Last Updated on STN: 19970203
Entered Medline: 19820109

L12 ANSWER 20 OF 70 MEDLINE on STN
AN 78167199 MEDLINE
DN 78167199 PubMed ID: 274175
TI Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
AU Lauzon G J; Paterson A R; Belch A W
SO CANCER RESEARCH, (1978 Jun) 38 (6) 1730-3.
Journal code: 2984705R. ISSN: 0008-5472.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 197807
ED Entered STN: 19900314
Last Updated on STN: 19970203
Entered Medline: 19780726

L12 ANSWER 21 OF 70 MEDLINE on STN
AN 76251112 MEDLINE
DN 76251112 PubMed ID: 60073
TI 5-Azacytidine. A new anticancer drug with effectiveness in acute **myelogenous leukemia**.
AU Von Hoff D D; Slavik M; Muggia F M

SO ANNALS OF INTERNAL MEDICINE, (1976 Aug) 85 (2) 237-45. Ref: 73
Journal code: 0372351. ISSN: 0003-4819.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 197609
ED Entered STN: 19900313
Last Updated on STN: 19970203
Entered Medline: 19760925

L12 ANSWER 22 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:90082 BIOSIS
DN PREV200100090082
TI Simultaneous treatment with 1-beta-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells.
AU Takemura, Haruyuki; Urasaki, Yoshimasa; Yoshida, Akira; Fukushima, Toshihiro; Ueda, Takanori (1)
CS (1) First Department of Internal Medicine, Fukui Medical University, 23-3, Shimoaizuki, Matsuoka, Fukui, 910-1193 Japan
SO Cancer Research, (January 1, 2001) Vol. 61, No. 1, pp. 172-177. print.
ISSN: 0008-5472.
DT Article
LA English
SL English

L12 ANSWER 23 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:272737 BIOSIS
DN PREV200000272737
TI Cross-resistance to ara-C and daunorubicin induced by simultaneous treatment with both drugs showed a combination-specific mechanism in HL60/AD cells.
AU Takemura, Haruyuki (1); Urasaki, Yoshimasa (1); Yoshida, Akira (1); Fukushima, Toshihiro (1); Ueda, Takanori (1)
CS (1) Fukui Med Univ, Fujui Japan
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2000) No. 41, pp. 762. print..
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X.
DT Conference
LA English
SL English

L12 ANSWER 24 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:214465 BIOSIS
DN PREV200000214465
TI Mitochondrial respiratory function is a necessary step for apoptosis signaling induced by TAS-106 (3'-C-ethynyl-**cytidine**.
AU Higuchi, M. (1); Azuma, A.; Matsuda, A.; Sasaki, T.; Fukushima, M.
CS (1) Hokkaido Univ, Sapporo Japan
SO Proceedings of the American Association for Cancer Research Annual Meeting, (March, 2000) No. 41, pp. 156.
Meeting Info.: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X.
DT Conference
LA English
SL English

L12 ANSWER 25 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:198019 BIOSIS
DN PREV200000198019

TI Visual loss following high-dose cytosine arabinoside (ARA-C.
AU Schwartz, Joseph (1); Alster, Yair; Ben-Tal, Ofira; Lowenstein, Anat
CS (1) Department of Hematology, Tel-Aviv Sourasky Medical Center, 6 Weizman St., Tel-Aviv, 64239 Israel
SO European Journal of Haematology, (March, 2000) Vol. 64, No. 3, pp. 208-209.
ISSN: 0902-4441.
DT Article; Letter
LA English
SL English

L12 ANSWER 26 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1998:274149 BIOSIS
DN PREV199800274149
TI Telomerase from human leukemia cells: Properties and its interaction with deoxynucleoside analogues.
AU Pai, Rekha B.; Pai, S. Balakrishna; Kukhanova, Marina; Dutschman, Ginger E.; Guo, Xin; Cheng, Yung-Chi (1)
CS (1) Dep. Pharmacol., Yale Sch. Med., Yale Univ., 333 Cedar St., New Haven, CT 06510 USA
SO Cancer Research, (May 1, 1998) Vol. 58, No. 9, pp. 1909-1913.
ISSN: 0008-5472.
DT Article
LA English

L12 ANSWER 27 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1991:457552 BIOSIS
DN BA92:102332
TI HEMIN ENHANCES THE SENSITIVITY OF ERYTHROLEUKEMIA CELLS TO 1-BETA-D ARABINOFURANOSYLCYTOSINE BY BOTH ACTIVATION OF DEOXYCYTIDINE KINASE AND REDUCTION OF **CYTIDINE** DEAMINASE ACTIVITY.
AU HONMA Y; ONOZUKA Y; OKABE-KADO J; KASUKABE T; HOZUMI M
CS DEP. CHEMOTHERAPY, SAITAMA CANCER CENT., RES. INST., INA, SAITAMA-362, JPN.
SO CANCER RES, (1991) 51 (17), 4335-4538.
CODEN: CNREA8. ISSN: 0008-5472.
FS BA; OLD
LA English

L12 ANSWER 28 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1988:506365 BIOSIS
DN BA86:127049
TI EFFECT OF CYTOSINE ARABINOSIDE ON THE HUMAN IMMUNOSYSTEM METABOLISM AND CYTOTOXICITY STUDIED WITH MITOGEN-STIMULATED NORMAL BLOOD LYMPHOCYTES IN-VITRO.
AU VILPO J A; VEROMAA T; EEROLA E
CS LAB. MOLECULAR HEMATOLOGY, BIOCENTER, UNIV. OULU, SF-90220 OULU, FINLAND.
SO INT J IMMUNOPHARMACOL, (1988) 10 (5), 593-600.
CODEN: IJIMDS. ISSN: 0192-0561.
FS BA; OLD
LA English

L12 ANSWER 29 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1987:317770 BIOSIS
DN BA84:37277
TI PRESENCE OF **CYTIDINE** 5' MONOPHOSPHO-N-ACETYLNEURAMINIC ACID GALACTOSYL-BETA-1-3-N-ACETYL-D-GALACTOSAMINE ALPHA-2-3-SIALYLTRANSFERASE IN NORMAL HUMAN LEUKOCYTES AND INCREASED ACTIVITY OF THIS ENZYME IN GRANULOCYTES FROM CHRONIC **MYELOGENOUS LEUKEMIA** PATIENTS.
AU BAKER M A; KANANI A; BROCKHAUSEN I; SCHACHTER H; HINDENBURG A; TAUB R N
CS TORONTO GENERAL HOSP., MULOCK LARKIN WING 1-005, TORONTO, ONTARIO M5G 1L7, TORONTO, ONTARIO, CANADA.
SO CANCER RES, (1987) 47 (11), 2763-2766.
CODEN: CNREA8. ISSN: 0008-5472.

FS BA; OLD
LA English

L12 ANSWER 30 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1984:332606 BIOSIS
DN BA78:69086
TI A RANDOMIZED COMPARISON OF POST REMISSION THERAPY IN ACUTE **MYELOGENOUS LEUKEMIA** A SOUTHEASTERN CANCER STUDY GROUP USA TRIAL.
AU VOGLER W R; WINTON E F; GORDON D S; RANEY M R; GO B; MEYER L
CS 718 WOODRUFF MEMORIAL BUILDING, EMORY UNIVERSITY, ATLANTA, GA. 30322.
SO BLOOD, (1984) 63 (5), 1039-1045.
CODEN: BLOOAW. ISSN: 0006-4971.
FS BA; OLD
LA English

L12 ANSWER 31 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1984:114891 BIOSIS
DN BR27:31383
TI PROLONGED SURVIVAL IN ACUTE **MYELOGENOUS LEUKEMIA** WITHOUT MAINTENANCE CHEMO THERAPY.
AU CHAMPLIN R; GALE R P; ELASHOFF R; JACOBS A; BOCCIA R; FOON K; ZIGHELBOIM J
CS BONE MARROW TRANSPLANTATION PROGRAM, UCLA SCH. MED., CENT. HEALTH SCI., LOS ANGELES, CALIF. 90024, USA.
SO Lancet, (1984) 1 (8382), 894-896.
CODEN: LANCAO. ISSN: 0023-7507.
FS BR; OLD
LA English

L12 ANSWER 32 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1984:101801 BIOSIS
DN BR27:18293
TI STEM CELL DEFECTS AFTER INTENSIVE CYTO REDUCTIVE THERAPY FOR ACUTE **MYELOGENOUS LEUKEMIA**.
AU WEINER R S; OBLON D J; GROSS M A
CS DIV. OF MED. ONCOL., UNIV. OF FLA., GAINESVILLE, 32610 USA.
SO 12TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY, LONDON, ENGLAND, JULY 10-14, 1983. EXP HEMATOL (LAWRENCE). (1983) 11 (SUPPL 14), 41.
CODEN: EXHMA6. ISSN: 0301-472X.
DT Conference
FS BR; OLD
LA English

L12 ANSWER 33 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1984:38983 BIOSIS
DN BR26:38983
TI THE THERAPEUTIC EFFECT OF 5 AZA **CYTIDINE** ON THE **MYELOGENOUS LEUKEMIA** OF 13-N GUINEA-PIG.
AU XU Y H; HSU C K
CS DEP. PHYSIOL., CHANGSHA, HUNAN, PEOPLE'S REPUBLIC CHINA.
SO 12TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY FOR EXPERIMENTAL HEMATOLOGY, LONDON, ENGLAND, JULY 10-14, 1983. EXP HEMATOL (LAWRENCE). (1983) 11 (SUPPL 14), 173.
CODEN: EXHMA6. ISSN: 0301-472X.
DT Conference
FS BR; OLD
LA English

L12 ANSWER 34 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1983:3353 BIOSIS
DN BR24:3353
TI TREATMENT OF ACUTE **MYELOGENOUS LEUKEMIA** IN CHILDREN.
AU WEINSTEIN H J; CORAL F S; CAMITAA B M; GELBER R D; FREI E III
CS HARVARD MED. SCH., CHILDREN'S HOSP., BOSTON.

SO ANNUAL MEETING OF THE AMERICAN PEDIATRIC SOCIETY AND THE SOCIETY FOR PEDIATRIC RESEARCH, WASHINGTON, D.C., USA, MAY 11-13, 1982. PEDIATR RES. (1982) 16 (4 PART 2), 218A.
CODEN: PEREBL. ISSN: 0031-3998.
DT Conference
FS BR; OLD
LA English

L12 ANSWER 35 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:304886 BIOSIS
DN BA74:77366
TI 5 AZA **CYTIDINE** IN REFRACTORY ACUTE LEUKEMIA.
AU CASE D C JR
CS DIV OF HEMATOL., DEP. OF MED., MAINE MED. CENT., PORTLAND, OREG. MAINE 04102, USA.
SO ONCOLOGY (BASEL), (1982) 39 (4), 218-221.
CODEN: ONCOBS. ISSN: 0030-2414.
FS BA; OLD
LA English

L12 ANSWER 36 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:239196 BIOSIS
DN BA74:11676
TI TREATMENT OF THE BLAST CRISIS OF CHRONIC **MYELOGENOUS LEUKEMIA** WITH 5 AZA **CYTIDINE** AND VP-16-213 VEPESIDE.
AU SCHIFFER C A; DEBELLIS R; KASDORF H; WIERNIK P H
CS BALTIMORE CANCER RES. CENT., 22 S. GREENE ST., BALTIMORE, MD. 21201.
SO CANCER TREAT REP, (1982) 66 (2), 267-272.
CODEN: CTRRDO. ISSN: 0361-5960.
FS BA; OLD
LA English

L12 ANSWER 37 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:195586 BIOSIS
DN BA73:55570
TI TREATMENT OF PATIENTS OVER 50 YEARS OF AGE WITH ACUTE **MYELOGENOUS LEUKEMIA** WITH A COMBINATION OF RUBIDAZONE AND CYTOSINE ARABINOSIDE VINCRISTINE AND PREDNISONE.
AU KEATING M J; MCCREDIE K B; BENJAMIN R S; BODNEY G P; ZANDER A; SMITH T L; FREIREICH E J
CS DEP. OF DEVLOPMENTAL THERAPEUTICS, M. D. ANDERSON HOSPITAL AND TUMOR INSTITUTE, 6723 BERTNER, HOUSTON, TEX. 77030.
SO BLOOD, (1981) 58 (3), 584-591.
CODEN: BLOOAW. ISSN: 0006-4971.
FS BA; OLD
LA English

L12 ANSWER 38 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:188481 BIOSIS
DN BA73:48465
TI AN IN-VITRO MODEL FOR ACUTE **MYELOGENOUS LEUKEMIA** CHEMO THERAPY.
AU KOEFFLER H P; LOWE L; YEN J
CS UNIV. CALIFORNIA, DEP. MED., CENT. HEALTH SCI., LOS ANGELES, CALIF. 90024.
SO CANCER (PHILA), (1981) 48 (9), 1958-1963.
CODEN: CANCAR. ISSN: 0008-543X.
FS BA; OLD
LA English

L12 ANSWER 39 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1982:20836 BIOSIS
DN BR22:20836
TI PROGNOSTIC FACTORS AFFECTING REMISSION INDUCTION AND DURATION IN ADULT ACUTE **MYELOGENOUS LEUKEMIA**.
AU VOGLER W R; WINTON E F; GORDON D S; JARRELL R; LEFANTE J

CS EMORY UNIV., ATLANTA, GEORGIA 3032.
SO 17TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, INC., WASHINGTON, D.C., USA, APRIL 30-MAY 2, 1981. PROC AM ASSOC CANCER RES CLIN ONCOL. (1981) 22 (0), 489.
CODEN: PAAOD8.
DT Conference
FS BR; OLD
LA English

L12 ANSWER 40 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1981:7098 BIOSIS
DN BR20:7098
TI TREATMENT OF THE RESISTANT PHASE OF CHRONIC **MYELOGENOUS LEUKEMIA** WITH 5 AZA **CYTIDINE** AND VP-16-213 VEPESIDE.
AU SCHIFFER C A; DIBELLIS R; KASDORF H; WIERNIK P H
CS NCI-PAHO COLLAB. CANCER TREATMENT RES. PROG., BALTIMORE, MD. 21201, USA.
SO 71ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, SAN DIEGO, CALIF., USA, MAY 28-31, 1980. PROC AM ASSOC CANCER RES AM SOC CLIN ONCOL. (1980) 21 (0), 163.
CODEN: PAAOD8.
DT Conference
FS BR; OLD
LA English

L12 ANSWER 41 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1980:156809 BIOSIS
DN BA69:31805
TI EVALUATION OF CYCLO **CYTIDINE** IN CHILDREN WITH ADVANCED ACUTE LEUKEMIA AND SOLID TUMORS.
AU FINKLESTEIN J Z; HIGGINS G; KRIVIT W; HAMMOND D
CS OPER. OFF., CHILD. CANCER STUDY GROUP, 1721 N. GRIFFIN AVE., LOS ANGELES, CALIF. 90031, USA.
SO CANCER TREAT REP, (1979) 63 (8), 1331-1334.
CODEN: CTRRDO. ISSN: 0361-5960.
FS BA; OLD
LA English

L12 ANSWER 42 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1980:110324 BIOSIS
DN BR19:47822
TI SEVERE RENAL TUBULAR DYS FUNCTION DURING 5 AZA **CYTIDINE** CHEMO THERAPY.
AU COLLINS A J; VOGELZANG N J; BLOOMFIELD C D; PETERSON B A
CS UNIV. MINN., MINNEAPOLIS, MINN., USA.
SO 52ND ANNUAL MEETING OF THE CENTRAL SOCIETY FOR CLINICAL RESEARCH, CHICAGO, ILL., USA, NOV. 1-3, 1979. CLIN RES. (1979) 27 (4), 708A.
CODEN: CLREAS. ISSN: 0009-9279.
DT Conference
FS BR; OLD
LA English

L12 ANSWER 43 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1980:68698 BIOSIS
DN BR19:6196
TI CYCLO **CYTIDINE** AND ITS MODE OF ACTION.
AU KURETANI K; HOSHI A
CS PHARMACOL. DIV., NATL. CANCER CENT. RES. INST., CHUO, TOKYO 104, JPN.
SO CARTER, S. K. ET AL. (ED.). PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM OF THE PRINCESS TAKAMATSU CANCER RESEARCH FUND, VOL. 8. ADVANCES IN CANCER CHEMOTHERAPY; TOKYO, JAPAN, 1977. XVII+506P. UNIVERSITY PARK PRESS: BALTIMORE, MD., USA; JAPAN SCIENTIFIC SOCIETIES PRESS: TOKYO, JAPAN. ILLUS. (1978 (RECD 1979)) 0 (0), P119-128.
CODEN: PPTCBY. ISBN: 0-8391-1317-.
FS BR; OLD
LA English

L12 ANSWER 44 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1978:191327 BIOSIS
DN BA66:3824
TI PYRIMIDINE NUCLEOSIDE MONO PHOSPHATE KINASE EC-2.7.4.14 FROM HUMAN LEUKEMIC BLAST CELLS.
AU HANDE K R; CHABNER B A
CS NATL. INST. HEALTH, ROOM 6N119, BUILD. 10, BETHESDA, MD. 20014, USA.
SO CANCER RES, (1978) 38 (3), 579-585.
CODEN: CNREA8. ISSN: 0008-5472.
FS BA; OLD
LA English

L12 ANSWER 45 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1978:90222 BIOSIS
DN BR15:33722
TI TREATMENT OF REFRACTORY ACUTE **MYELOGENOUS LEUKEMIA** WITH 5 AZA **CYTIDINE** PLUS BETA DEOXY THIO GUANOSINE.
AU OMURA G A
SO Proc. Am. Assoc. Cancer Res., (1977) 18, 25.
CODEN: PAACA3. ISSN: 0569-2296.
DT Conference
FS BR; OLD
LA Unavailable

L12 ANSWER 46 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1978:70838 BIOSIS
DN BR15:14338
TI RHABDO MYOLYSIS AS A COMPLICATION OF 5 AZA **CYTIDINE**.
AU KOEFFLER H P; HASKELL C M
SO Cancer Treat. Rep., (1978) 62 (4), 573-574.
CODEN: CTRRDO. ISSN: 0361-5960.
FS BR; OLD
LA Unavailable

L12 ANSWER 47 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1978:49726 BIOSIS
DN BR14:49726
TI POTENTIAL ADVANCES IN THE CLINICAL USE OF CYTOSINE ARABINOSIDE.
AU HO D H W
SO Cancer Treat. Rep., (1977) 61 (4), 717-722.
CODEN: CTRRDO. ISSN: 0361-5960.
FS BR; OLD
LA Unavailable

L12 ANSWER 48 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1977:6118 BIOSIS
DN BR13:6118
TI CONTINUOUS INTRA VENOUS INFUSION OF CYCLO **CYTIDINE** IN ADULT ACUTE **MYELOGENOUS LEUKEMIA** PATIENTS.
AU IBUKA T; TAKENAKA T; SASAKI T; INOUE K; MINATO K; SAKANO T; SHIMOYAMA M; KONDA T; SAKAI Y; ET AL.
SO Nippon Ketsueki Gakkai Zasshi, (1975 (RECD 1976)) 38 (4), 396-397.
CODEN: NKGZAE. ISSN: 0001-5806.
DT Conference
FS BR; OLD
LA Unavailable

L12 ANSWER 49 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1976:238155 BIOSIS
DN BA62:68155
TI 5 AZA **CYTIDINE** A NEW ANTI CANCER DRUG WITH EFFECTIVENESS IN ACUTE **MYELOGENOUS LEUKEMIA**.
AU VON HOFF D D; SLAVIK M; MUGGIA F M
SO ANN INTERN MED, (1976) 85 (2), 237-245.

CODEN: AIMEAS. ISSN: 0003-4819.
FS BA; OLD
LA Unavailable

L12 ANSWER 50 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1975:96778 BIOSIS
DN BR11:96778
TI CYCLO **CYTIDINE** NSC-145668 STUDY IN THE TREATMENT OF ACUTE LEUKEMIA.
AU YAMADA K; KIMURA K
SO ITO, YOHEI AND RAY M. DUTCHER (ED.). BIBLIOTHECA HAEMATOLOGICA, NO. 40. COMPARATIVE LEUKEMIA RESEARCH 1973. LEUKEMOGENESIS. PROCEEDINGS OF THE VITH INTERNATIONAL SYMPOSIUM. NAGOYA AND ISE-SHIMA, JAPAN, 1973. XXX+810P. ILLUS. S. KARGER: BASEL, SWITZERLAND; NEW YORK, N.Y., U.S.A. (1975) 753-754.
ISBN: 3-8055-2090-5.
FS BR; OLD
LA Unavailable

L12 ANSWER 51 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1974:132930 BIOSIS
DN BA57:32630
TI TREATMENT OF ACUTE LEUKEMIA WITH 5 AZA **CYTIDINE** NSC-102816.
AU MCCREDIE K B; BODEY G P; BURGESS M A; GUTTERMAN J U; RODRIGUEZ V; SULLIVAN M P
SO CANCER CHEMOTHER REP PART 1, (1973) 57 (3), 319-323.
CODEN: CCROBU. ISSN: 0576-6559.
FS BA; OLD
LA Unavailable

L12 ANSWER 52 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1974:127490 BIOSIS
DN BA57:27190
TI 5 AZA **CYTIDINE** A NEW ACTIVE AGENT FOR THE TREATMENT OF ACUTE LEUKEMIA.
AU KARON M; SIEGER L; LEIMBROCK S; FINKLESTEIN J Z; NESBIT M E; SWANEY J J
SO BLOOD J HEMATOL, (1973) 42 (3), 359-365.
CODEN: BLOOAW. ISSN: 0006-4971.
FS BA; OLD
LA Unavailable

L12 ANSWER 53 OF 70 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AN 1973:61141 BIOSIS
DN BR09:61141
TI 5 AZA **CYTIDINE** EFFECTIVE TREATMENT FOR ACUTE LEUKEMIA IN CHILDREN.
AU KARON M; SIEGER L; LEIMBROCK S; NESBIT M; FINKLESTEIN J
SO Proc. Am. Assoc. Cancer Res., (1973) 14, 94.
CODEN: PAACA3. ISSN: 0569-2296.
DT Conference
FS BR; OLD
LA Unavailable

L12 ANSWER 54 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2003:609844 CAPLUS
TI Method for treating chronic **myelogenous leukemia** combined with some resistance to imatinib mesylate using DNA methylation inhibitor to mitigate imatinib mesylate resistance
IN Lyons, John
PA USA
SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003147813	A1	20030807	US 2002-71849	20020207
	WO 2003065995	A2	20030814	WO 2003-US3537	20030206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2002-71849	A1	20020207		
	US 2002-206854	A1	20020726		

L12 ANSWER 55 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:606409 CAPLUS
DN 136:303672
TI Relationship between clinical efficacy and intracellular levels of dCK and CDA in acute leukemia
AU Chen, Fangyuan; Lu, Hongmin; Xuan, Zhenghau; Han, Jieying; Teng, Ye; Ouyang, Renrong
CS Department of Hematology, Renji Hospital, Shanghai Second Medical University, Shanghai, 200001, Peop. Rep. China
SO Shanghai Yixue (2001), 24(5), 266-269
CODEN: SIHSD8; ISSN: 0253-9934
PB Shanghai Yixue Bianji Weiyuanhui
DT Journal
LA Chinese

L12 ANSWER 56 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:335842 CAPLUS
DN 135:251531
TI Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low **cytidine** deaminase activity
AU Gourdeau, Henriette; Bibeau, Lucie; Ouellet, France; Custeau, Dominique; Bernier, Louise; Bowlin, Terry
CS BioChem Pharma Inc., Laval, QC, H7V 4A7, Can.
SO Cancer Chemotherapy and Pharmacology (2001), 47(3), 236-240
CODEN: CCPHDZ; ISSN: 0344-5704
PB Springer-Verlag
DT Journal
LA English
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 57 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:327881 CAPLUS
DN 135:236001
TI Cyclopentenyl cytosine increases the phosphorylation and incorporation into DNA of arabinofuranosyl cytosine in a myeloid leukemic cell-line
AU Verschuur, A. C.; Van Gennip, A. H.; Leen, R.; Voute, P. A.; Van Kuilenburg, A. B. P.
CS Academic Medical Centre, Departments of Pediatrics and Clinical Chemistry, Laboratory of Genetic Metabolic Diseases, University of Amsterdam, Amsterdam, 1100 DE, Neth.
SO Advances in Experimental Medicine and Biology (2000), 486(Purine and Pyrimidine Metabolism in Man X), 311-317
CODEN: AEMBAP; ISSN: 0065-2598
PB Kluwer Academic/Plenum Publishers
DT Journal

LA English
RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 58 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:57970 CAPLUS
DN 134:261001
TI Simultaneous treatment with 1-.beta.-D-arabinofuranosylcytosine and daunorubicin induces cross-resistance to both drugs due to a combination-specific mechanism in HL60 cells
AU Takemura, Haruyuki; Urasaki, Yoshimasa; Yoshida, Akira; Fukushima, Toshihiro; Ueda, Takanori
CS First Department of Internal Medicine, Fukui Medical University, Fukui, 910-1193, Japan
SO Cancer Research (2001), 61(1), 172-177
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 59 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:601787 CAPLUS
DN 134:110183
TI The pharmacodynamic basis for the increased antileukemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukemia with a high proliferative activity
AU Braess, J.; Voss, S.; Jahns-Streubel, G.; Schoch, C.; Haferlach, T.; Kern, W.; Keye, S.; Schleyer, E.; Hiddemann, W.
CS Department of Internal Medicine III. University Hospital Grosshadern, Ludwig-Maximilians University, Munich, 81377, Germany
SO British Journal of Haematology (2000), 110(1), 170-179
CODEN: BJHEAL; ISSN: 0007-1048
PB Blackwell Science Ltd.
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 60 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:732639 CAPLUS
DN 132:329490
TI **Cytidine** deaminase - the methodological relevance of AraC deamination for ex vivo experiments using cultured cell lines, fresh leukemic blasts, and normal bone marrow cells
AU Braess, J.; Pfortner, J.; Kern, W.; Hiddemann, W.; Schleyer, E.
CS Forschungslabor A, Medical Clinic III, Klinikum Grosshadern, Munich, D-81377, Germany
SO Annals of Hematology (1999), 78(11), 514-520
CODEN: ANHEE8; ISSN: 0939-5555
PB Springer-Verlag
DT Journal
LA English
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 61 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:466163 CAPLUS
DN 129:225253
TI Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute **myelogenous leukemia**
AU Gandhi, Varsha; Xu, Yi-Zheng; Estey, Elihu
CS Department of Clinical Investigation, The University of Texas M. D.

Anderson Cancer Center, Houston, TX, 77030, USA
SO Clinical Cancer Research (1998), 4(7), 1719-1726
CODEN: CCREF4; ISSN: 1078-0432
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 62 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:273450 CAPLUS
DN 129:64665
TI Telomerase from human leukemia cells: properties and its interaction with deoxynucleoside analoges
AU Pai, Rekha B.; Pai, S. Balakrishna; Kukhanova, Marina; Dutschman, Ginger E.; Guo, Xin; Cheng, Yung-Chi
CS Department of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, 06510, USA
SO Cancer Research (1998), 58(9), 1909-1913
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 63 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:79798 CAPLUS
DN 126:152479
TI YNK01, an oral cytosine arabinoside derivative in acute myeloid leukemia and chronic myeloid leukemia
AU Heussner, P.; Willemze, R.; Ganser, A.; Hanauske, A.; Amadori, S.; Heil, G.; Schleyer, E.; Hiddemann, W.; Selbach, J.; et al.
CS Department of Hematology and Oncology, University of Medicine, Rostock, Germany
SO Haematology and Blood Transfusion (1997), 38(Acute Leukemias VI), 882-885
CODEN: HBTRDV; ISSN: 0171-7111
PB Springer
DT Journal
LA English

L12 ANSWER 64 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:403388 CAPLUS
DN 122:205177
TI Method for treating cancer using the copper complex of S-(methylthio)-DL-homocysteine or the L-enantiomorph
IN Rabinovitz, Marco; Fisher, Joyce M.
PA United States Dept. of Health and Human Services, USA
SO U.S., 17 pp. Cont.-in-part of U.S. 5,124,351.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5385933	A	19950131	US 1992-901261	19920619
	US 315911	A0	19900115	US 1989-315911	19890227
	US 5124351	A	19920623		
PRAI	US 1989-315911		19890227		

L12 ANSWER 65 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1991:574245 CAPLUS
DN 115:174245
TI Hemin enhances the sensitivity of erythroleukemia cells to 1-.beta.-D-arabinofuranosylcytosine by both activation of deoxycytidine

kinase and reduction of **cytidine** deaminase activity
AU Honma, Yoshio; Onozuka, Yuji; Okabe-Kado, Junko; Kasukabe, Takashi; Hozumi, Motoo
CS Dep. Chemother., Saitama Cancer Cent. Res. Inst., Ina, 362, Japan
SO Cancer Research (1991), 51(17), 4535-8
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

L12 ANSWER 66 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1990:569637 CAPLUS
DN 113:169637
TI Human leukemic myeloblasts and myeloblastoid cells contain the enzyme **cytidine**-5'-monophosphate-N-acetylneuraminic acid Gal.beta.1-3-GalNac.alpha.(203)-sialyltransferase
AU Kanani, Amita; Sutherland, D. Robert; Fibach, Eitan; Matta, Kushi L.; Hindenburg, Alex; Brockhausen, Inka; Kuhns, William; Taub, Robert N.; Van den Eijnden, Dirk H.; Baker, Michael A.
CS Dep. Med., Toronto Gen. Hosp., Toronto, ON, M5G 2C4, Can.
SO Cancer Research (1990), 50(16), 5003-7
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

L12 ANSWER 67 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1987:513462 CAPLUS
DN 107:113462
TI Presence of **cytidine** 5'-monophospho-N-acetylneuraminic acid:Gal.beta.1-3GalNAc-R .alpha.(2-3-sialyltransferase in normal human leukocytes and increased activity of this enzyme in granulocytes from chronic **myelogenous leukemia** patients
AU Baker, M. A.; Kanani, A.; Brockhausen, I.; Schachter, H.; Hindenburg, A.; Taub, R. N.
CS Toronto Gen. Hosp., Univ. Toronto, Toronto, ON, M5G 1L7, Can.
SO Cancer Research (1987), 47(11), 2763-6
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

L12 ANSWER 68 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1982:574427 CAPLUS
DN 97:174427
TI Enzymic studies on possible improvement of cytosine arabinoside treatment
AU Mejer, J.
CS Dep. Intern. Med. C, Bispebjerg Hosp., Copenhagen, DK-2500, Den.
SO Scandinavian Journal of Clinical and Laboratory Investigation (1982), 42(5), 401-6
CODEN: SJCLAY; ISSN: 0036-5513
DT Journal
LA English

L12 ANSWER 69 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1981:597080 CAPLUS
DN 95:197080
TI An in vitro model for acute **myelogenous leukemia** chemotherapy
AU Koeffler, H. Phillip; Yen, James; Lowe, Leslie
CS Sch. Med., Univ. California, Los Angeles, CA, USA
SO Cancer (New York, NY, United States) (1981), 48(9), 1958-63
CODEN: CANCAR; ISSN: 0008-543X
DT Journal
LA English

L12 ANSWER 70 OF 70 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1978:183118 CAPLUS

DN 88:183118
TI Clinical, biological, and biochemical effects of Pyrazofurin
AU Cadman, Edwin C.; Dix, Douglas E.; Handschumacher, Robert E.
CS Dep. Pharmacol., Yale Univ. Sch. Med., New Haven, CT, USA
SO Cancer Research (1978), 38(3), 682-8
CODEN: CNREA8; ISSN: 0008-5472
DT Journal
LA English

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	145.40	145.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.95	-1.95

STN INTERNATIONAL LOGOFF AT 15:16:17 ON 20 AUG 2003